This study was performed on adult New Zealand White rabbits that were housed in an AALAC-approved facility at the University of Minnesota. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Minnesota and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the animal care policy of the National Institutes of Health.
Rabbits were anesthetized with an intramuscular injection of ketamine and xylazine (1:1, 10 and 2 mg/kg, respectively). One set of 12 rabbits was subjected to recession surgery. One randomly selected superior rectus muscle in each animal was detached from the sclera. The muscle insertion was recessed 7 mm and sutured to the sclera with Vicryl 7-0 (polyglactin 910; Ethicon, Somerville, NJ). A second set of 10 rabbits was subjected to a tenotomy procedure, in which one randomly selected superior rectus muscle was detached from the sclera and then sutured directly to the site of its original insertion. A third set of six adult rabbit superior rectus muscles that had undergone no surgical interventions served as control muscles. Immediately after surgery, tobramycin-dexamethasone combination ointment (Alcon, Fort Worth, TX) was applied to the conjunctival cul-de-sac. One week after surgery, six recessed and six tenotomized rabbits each received intraperitoneal injections of BrdU in sterile isotonic saline every 2 hours for 12 hours, at a dose of 50 mg/kg body weight. Similarly, 2 weeks after surgery, BrdU injections were performed in the second group of rabbits. Twenty-four hours after the last injection, the animals were euthanatized by an overdose of barbiturate anesthesia. All superior and inferior rectus muscles were removed, embedded in tragacanth gum, frozen in 2-methylbutane chilled to a slurry on liquid nitrogen, and stored at −80°C until processed.
Cryostat sections were prepared at 12 μm, and serial sections were immunostained for one of the following molecules: fast (1:40), slow (1:40), developmental (1:20), and neonatal (1:20) MyHC isoforms (Vector Laboratories., Burlingame, CA); Pax7 (1:100; Hybridoma Bank, Iowa City, IA); BrdU (1:20,000; Sigma, St. Louis, MO); or dystrophin (1:20; Vector Laboratories). Immunostaining used standard methods.
12 Briefly, the sections were blocked with 10% normal horse serum; incubated for 1 hour in primary antibody at room temperature, followed by sequential incubation in reagents from the ABC kit (VectaElite; Vector Laboratories), labeled with peroxidase; and developed with diaminobenzidine with heavy metals. In addition, sections were stained with hematoxylin and eosin and used for myofiber cross-sectional area measurements. The percentage of cells positive for each MyHC isoform as well as the mean cross-sectional areas were determined by manual tracing of myofibers with morphometry software (Nova Prime; Bioquant, Nashville, TN). We counted Pax7-positive satellite cells and BrdU-labeled satellite cells, defined positionally in relation to dystrophin double-staining, by using our standard methodology.
13 Briefly, the proportion of labeled satellite cells, as defined by Pax7 staining or by positional localization of BrdU-labeling, as a percentage of the number of myofibers in a given microscopic field was calculated. For all measurements, data were collected in a minimum of four random fields in at least three separate cross sections within both the orbital and global layers of six rectus muscles and six control muscles for the recessed and four muscles each for the tenotomized muscles at each of the postsurgical survival times. Sections were chosen close to the insertional tendon and in the mid-belly region of the analyzed muscles. Thus, six slides were analyzed per muscle per staining parameter. All data are presented as the mean ± SEM. The percentage of positive cells was compared between the orbital and global layers and analyzed for statistical significance by using either an unpaired two-tailed
t-test (if two groups were being compared) or an analysis of variance (ANOVA) and Dunn's multiple comparison tests (Prism and Statmate software; GraphPad, San Diego, CA) for multiple group comparisons. An
F-test was used to verify that the variances were not significantly different. Data were considered significantly different if
P < 0.05.